Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
about
Molecular Imaging of Angiogenesis and Vascular Remodeling in Cardiovascular PathologyClinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3Stromal Targets for Fluorescent-Guided Oncologic SurgeryRadiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple IntegrinsPeptides as targeting probes against tumor vasculature for diagnosis and drug deliverySPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular diseaseQuantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue modelHigh-Throughput Approaches to the Development of Molecular Imaging Agents.Oncologic Angiogenesis Imaging in the clinic---how and why.Radiation-induced tumor neoantigens: imaging and therapeutic implications.Preclinical molecular imaging of tumor angiogenesis.Anatomical and molecular imaging of skin cancerMultimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrinApplication of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke.[(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosisCombinatorial peptide libraries: mining for cell-binding peptides.Potential role of vascular targeted therapy to combat against tumor.Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.Peptide-based probes for targeted molecular imaging.Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung CancerComparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG uptake in lymph node metastasis of differentiated thyroid cancer.Peptides and peptide hormones for molecular imaging and disease diagnosis2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.Autoradiography screening of potential positron emission tomography tracers for asymptomatic abdominal aortic aneurysms(44)Sc: an attractive isotope for peptide-based PET imaging.Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET99mTc-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI.Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides.One-step radiosynthesis of ¹⁸F-AlF-NOTA-RGD₂ for tumor angiogenesis PET imagingImmuno-PET imaging of tumor endothelial marker 8 (TEM8)Molecular imaging in myeloma precursor disease.PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide.alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.F-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging.Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECTAnti-angiogenic peptides for cancer therapeuticsPilot study of FPPRGD2 for imaging α(v)β(3) integrin--how integral are integrins?
P2860
Q26747500-E3B9A87E-C958-459C-9F21-C70C10705D66Q26771417-4AFC9138-400C-4638-8705-807FD6D78D36Q26774497-20FD683D-ACEB-4641-B8E3-FA8013011591Q26801806-F292C2EC-55C6-497D-80E7-0141C55FD38CQ27024850-F47F74C5-559C-469A-BA8C-D9ADAFCB070EQ28066121-585CB849-F7D5-4683-B4A2-D6FAE53C2516Q28729872-1C57C5D8-F768-4E46-B15B-947BE065C313Q30275493-37D73D6E-CE9F-4A4C-B3CF-19DC173ECD8FQ30472751-F1E67CF9-AC3D-40B8-87B7-24CEF21AB986Q30473856-945D96E3-F121-46D8-9541-D02A4D7AE6F3Q30475818-5F86AF84-F1CA-4D63-942C-43063AA1FCD2Q30476227-6B9B4812-9435-42F8-B270-371ACFE8B472Q30528396-80AD62AB-7143-491D-8605-636410E15D8EQ30832796-B957475C-D038-4448-945C-4335EA01D49CQ31095114-4A9A8DAD-93F7-40F5-BD2D-0BD94327F7A2Q31144876-8EEAB0B4-DF8B-4398-80A4-C1F5F6105BCBQ33470615-4B71F243-E944-4882-88E4-5E8EBB68C779Q33520512-A1862721-2778-49B3-9809-A23CEA98935FQ33526620-DA35E3B1-CDF9-4526-9717-7EF337796CC9Q33668360-8C150106-0ECB-422B-ADEF-7C26B9C2ECBAQ33767056-CC99F39E-ACEB-48A9-B45F-B946C1300664Q33793550-49332251-E7D4-4F4C-BF87-35AE792BECC5Q33846924-7237E8A1-B494-4304-8F0D-786CB0265C83Q33925952-A23F336E-90B4-481D-BE05-12BD578F25C9Q33956262-DB9A8C32-5911-4835-9494-6F7E0EDECA16Q33978492-043DE740-9D1C-4651-8161-565ACD05E44FQ34028144-9C5F302C-8F93-41D4-BA1B-D3D3FCC5D71CQ34235986-1D0C8943-9170-4763-B982-27BD88621DA7Q34252825-F367C8D8-6460-4C18-AD92-57EA8F157BCBQ34388500-ED8D98F8-8790-43C7-9500-89C36F08777CQ34420335-013BED52-4E0E-4040-8682-4929787CC9BCQ34435482-759B6491-4F91-4C74-A68A-736C70FD69D8Q34473434-7F85E42E-DA56-4FE0-AF57-692F834AEEBBQ34505016-8B5AA795-1893-4E3B-A182-0D05B6AA1915Q34677001-290BE0B1-7A8F-4670-BF93-EEC9E8FDEFFCQ34785222-B649906C-051E-4201-9A2D-FD4976873F59Q34912606-4639B1D8-0895-4AAE-B071-FBFA163C14DDQ34912643-91FF2792-8E00-4340-9962-A8F0CEA57A42Q35043016-ACC53E8B-641E-4812-8CBE-2137354922D6Q35103986-FC8B0236-0A2B-44CE-94EE-04E1CB57EED1
P2860
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Phase I trial of the positron- ...... 585 in breast cancer patients.
@en
Phase I trial of the positron-emitting Arg-Gly-Asp
@nl
type
label
Phase I trial of the positron- ...... 585 in breast cancer patients.
@en
Phase I trial of the positron-emitting Arg-Gly-Asp
@nl
prefLabel
Phase I trial of the positron- ...... 585 in breast cancer patients.
@en
Phase I trial of the positron-emitting Arg-Gly-Asp
@nl
P2093
P1476
Phase I trial of the positron- ...... 585 in breast cancer patients.
@en
P2093
Adil Al-Nahhas
Ai-Min Hui
Brian McParland
Carlo Palmieri
David Turton
Eric O Aboagye
Inger Oulie
Kaiyumars B Contractor
Laura M Kenny
Matthew Miller
P304
P356
10.2967/JNUMED.107.049452
P407
P577
2008-05-15T00:00:00Z